Drug promotion in the spotlight again
This article was originally published in Scrip
Executive Summary
The latest round in the wrangling between US drug regulators and manufacturers over inappropriate promotion got underway this week, as the FDA launched its Truthful Prescription Drug Advertising and Promotion Program, or ‘Bad Ad Program’ for short.